Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 1999

View Archived Issues

Company Profile: Xenna

Protein Design Labs: Q1 1999 highlights

Antioxidant di- and triacetic acid derivatives: preparation and use described by L'Oreal

New peptide tachykinin antagonists from Asahi Glass

Fluoroquinolones developed at Dainippon with broad-spectrum activity

Antiallergic/antiinflammatory agents in the Nikken Chemicals pipeline

Substituted indan derivatives with selective affinity for 5-HT1B receptors

Almirall Prodesfarma patents new series of selective COX-2 inhibitors

Telomerase inhibitors available for licensing from CRCT

AGN-192024 is more effective than timolol in lowering IOP in patients with glaucoma

Non-cysteine-containing FTase inhibitors from Abbott with good oral bioavailability

Ocufit SR provides sustained release of diclofenac into the sclera

Searle reports new COX-2 inhibitor series bearing a sulfonamide moiety

Potential anxiolytics/antidepressants under development at DuPont

Combinations of KRM-1648 with antiinflammatory drugs tested in MAC-infected mice

SnET2 photodynamic therapy stabilizes visual acuity in subfoveal choroidal neovascularization

Blopress finally cleared for marketing in Japan

Safe, dose-dependent MAO-B inhibition in healthy volunteers administered SL-34.0026

Takeda receives clearance to market lipid-lowering statin in Japan

CRCT establishes new tech transfer company for oncolytic drugs

Nycomed Amersham sells major interest in Nycomed Pharma

Amatine now marketed by Roberts in Canada

Ventana Genetics changes name, completes private financing

Oral fenoldopam useful for delaying progression of diabetic nephropathy

EMEA approves new formulation of Organon's fertility drug Puregon

Isis initiates phase II clinical trials of ISIS-2503

Proinflammatory effects demonstrated for SDZ-RAD in rat model of glomerulonephritis

Valentis up and running

Zonagen and Schering-Plough to forego FDA advisory panel review of Vasomax NDA

Genome Therapeutics attains milestone in alliance with Schering-Plough

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....